<img src="https://ml.globenewswire.com/Resource/Download/f1a5db68-ee4f-437f-b4e6-2b840ae6a536?size=2" nborder="0" align="left" hspace="5" vspace="5" title="roivantLogo.png" alt="Roivant Sciences"/>BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00 a.m. ET on Tuesday, September 8, 2026. To access the conference call by phone, please register online using this <a href="https://www.globenewswire.com/Tracker?data=mKKmRP2Bxelpif-yMO-tnAdyeIlhM17CsxjzEeXn-VQgFjJYPzZKy9QAlryPHBE4dNKtM5vGDfNCg4kbSsv3767-hxp6oK8QMr5yCzpAoD5fpPC_6eajBkeNbxSRPFXRyvsSmYPhVuEmh9ih5ZM8REd081XTNqZDsS9UVaPuaQA=" rel="nofollow" target="_blank" title="registration link">registration link</a>. The presentation and webcast details will also be available under “Events &amp; Presentations” in the Investors section of the Roivant website at <a href="https://www.globenewswire.com/Tracker?data=oprTA0Vuqi4XyrrZAmBuJvwh8xG9ylumS13ATMA7ATwTTZ9i05tFj4UDBrnZa-fgfyRdfMkDWRzlNdQ1LmEPQxnQbc8_Sw6oZueQo08o_FeZgRqo45THF1OmGfFjGtXIcOsRGn4BhAAz6gzw8KdSiv2kDzB4caAQG56SGZjL9Vo=" rel="nofollow" target="_blank" title="www.investor.roivant.com/news-events/events">www.investor.roivant.com/news-events/events</a>.  The archived webcast will be available on Roivant’s website after the conference call. About Roivant Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=uAd-f_pJXx2vRhOUaTR8x1_NwQyKvLjgXKlR1eFMZ1VGa4CYBOg928gkBy58bnVJpO3nGlTf4s9mUFAql5kgmQZqnFq2Q7IL0Sl-2CV7IibxM8vnD5u68PLaiaxhlP5FMF3wSaiJrixKoHPk3imSx0o4YfGzu6k8ksV9HtLKW7INSXzw1VmFqfqUpV4rbHnNa1HxG0KOaFvnyCxONjpOzufyE8q3spmxxGb0Ug4pEXs7taFdvvzqmoW7hV5Eb3edFosd9v-xCCo6aa8T5o38ig==" rel="nofollow" target="_blank" title="www.roivant.com">www.roivant.com</a>. Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: Investors Keyur Parekh <a href="https://www.globenewswire.com/Tracker?data=M6B9KVFTWWX7urY4CHFm32tBW1S59UbahRsiZVlSTJLbs1VFJgguKnSfzWfarMaEAWpf9xNVrr-ydGj2OT8kyqm47QXrji7SVOWK_LOzEegW_QaAOSrtXVkoGGKvKoCX" rel="nofollow" target="_blank" title="keyur.parekh@roivant.com">keyur.parekh@roivant.com</a>  Media Stephanie Lee <a href="https://www.globenewswire.com/Tracker?data=mpeC2Rc7RiFN-l_1s4b3xD0xoDy81lsIoHT8ixMzGfODlsbvSywoyhUCkP0mGQBMoOmF9j5mADQojP7O3NOzGAtffANehAQ-SwHrB8Kq_AXMoDC-PrR72AdhC-h1IiEq" rel="nofollow" target="_blank" title="stephanie.lee@roivant.com">stephanie.lee@roivant.com</a>  <img alt="" src='https://ml.globenewswire.com/media/YmFkYTAyNDktYjQ2OS00MGQwLTliZGUtMzI1MTFhNTZjNjIyLTEwMzAxODQtMjAyNi0wOS0wNi1lbg==/tiny/Roivant-Sciences-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn